Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

68.20 +0.02 (+0.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Why DEXCOM INC (NASDAQ:DXCM) Is a Standout High-Growth Stock in a Consolidation Phase.
Based on a technical and fundamental analysis of NASDAQ:DXCM we ask: Is DEXCOM INC (NASDAQ:DXCM) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
DexCom (DXCM): 3 Reasons We Love This Stock
Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up might have investors contemplating their next... 
Via StockStory
Topics Stocks
Is DexCom Gaining or Losing Market Support?
 
Via Benzinga
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Exploring the top movers within the S&P500 index during today's session.
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
DexCom Analysts Increase Their Forecasts After Q4 Earnings
 
Via Benzinga
Top S&P500 movers in Thursday's session
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Via The Motley Fool
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
From DexCom, Inc.
Via Business Wire
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest... 
Via StockStory
Topics Artificial Intelligence
Which S&P500 stocks are moving on Monday?
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried
The company is facing a regulatory setback. But one analyst doesn't expect that to impact its upcoming, potential approval. 
Via Investor's Business Daily
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements. 
Via Chartmill
Dexcom Appoints Renée Galá to Board of Directors
From DexCom, Inc.
Via Business Wire
DEXCOM INC (NASDAQ:DXCM)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Based on technical and fundamental analysis of NASDAQ:DXCM we find: DEXCOM INC (NASDAQ:DXCM) qualifies as a high growth stock and is consolidating. 
Via Chartmill
3 Growth Stocks to Buy and Hold Forever
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Dexcom Announces Upcoming Conference Presentation
From DexCom, Inc.
Via Business Wire
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom... 
Via StockStory
Topics Artificial Intelligence
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
These S&P500 stocks are moving in today's pre-market session
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
Insulet Earnings: What To Look For From PODD
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect. 
Via StockStory
iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. 
Via StockStory
What's going on in today's session: S&P500 movers
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday. 
Via Chartmill
Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom
DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts highlighted long-term growth potential. 
Via Benzinga
In today's session, there are S&P500 stocks with remarkable trading volume.
Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. 
Via Chartmill
Stocks Head For Weekly Gains, US Treasury Yields Fall Below 4.5%: What's Driving Markets Friday?
Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&P 500 and Nasdaq trading just above the flatline Friday. 
Via Benzinga
Topics Stocks
Discover which S&P500 stocks are making waves on Friday.
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Dexcom Q4 Earnings: Expanding Sales, New Products, Margin Pressure And More
Dexcom reported Q4 results, with revenue up 8%, beating estimates. CEO looks forward to unlocking next wave of global access. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.